N- (3- iodoprop- 2- enyl)- 2- beta- carbomethoxy- 3- (4- methylphenyl)nortropane

Also Known As:

(11C)PE2I; 123I-PE2I; 3H-labeled N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)nortropane; N-(3-iodoprop-2-enyl)-2-beta-carbomethoxy-3-(4'-tolyl)nortropane; N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)nortropane; PE2I-123I

Networked: 10 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Appel, Lieuwe: 2 articles (05/2022 - 01/2017)
2.	Lubberink, Mark: 2 articles (05/2022 - 01/2017)
3.	Nyholm, Dag: 2 articles (05/2022 - 01/2017)
4.	Farde, Lars: 2 articles (02/2012 - 02/2005)
5.	Halldin, Christer: 2 articles (02/2012 - 02/2005)
6.	Jucaite, Aurelija: 2 articles (02/2012 - 02/2005)
7.	Baulieu, Jean-Louis: 2 articles (07/2003 - 05/2003)
8.	Chalon, Sylvie: 2 articles (07/2003 - 05/2003)
9.	Guilloteau, Denis: 2 articles (07/2003 - 05/2003)
10.	Prunier, Caroline: 2 articles (07/2003 - 05/2003)

Related Diseases

1.	Parkinsonian Disorders (Parkinsonism) 05/01/2022 - "This proof-of-concept study used retrospectively a database with 125 pairs of co-registered 68Ge-AC maps and T1w MR images from anatomical normal subjects and a validation dataset comprising dynamic [11C]PE2I PET data from nine patients with Parkinsonism. " 01/01/2017 - "Twelve subjects with parkinsonism and seventeen healthy controls underwent 80 min dynamic [11C]PE2I PET scans. " 01/01/2017 - "Development of a clinically feasible [11C]PE2I PET method for differential diagnosis of parkinsonism using reduced scan duration and automated reference region extraction." 07/01/2003 - "Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT." 01/01/2017 - "Parametric images based on dynamic [11C]PE2I scans, showing dopamine transporter availability (BPND) and relative cerebral blood flow (R1), can be used in differential diagnosis of parkinsonism. "
2.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 02/01/2017 - "On day 7 and 14 after middle cerebral artery occlusion, [11C]PE2I binding levels were decreased. " 02/01/2017 - "[11C]PE2I binding to dopamine transporter was transiently increased on the ipsilateral side of the striatum at 2 days after middle cerebral artery occlusion. "
3.	Juvenile Myoclonic Epilepsy 02/15/2012 - "Quantitative PET analyses of regional [11C]PE2I binding to the dopamine transporter--application to juvenile myoclonic epilepsy."
4.	Tremor (Tremors) 10/01/2007 - "Tremor was not observed until striatal [11C]PE2I binding was reduced to about 15% of the pretreatment level and [beta-11C]DOPA uptake was reduced to about 34%. "
5.	Schizophrenia (Dementia Praecox) 01/01/2017 - "In order to address these issues, we used a high resolution positron emission tomograph and the selective DAT radioligand [11C]PE2I, coupled with a whole brain voxel-based analysis method to investigate DAT availability in striatal but also extra-striatal regions in 21 male chronic schizophrenia patients compared to 30 healthy male controls matched by age. "

Related Drugs and Biologics

1.	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)
2.	Raclopride
3.	Ligands
4.	Dihydroxyphenylalanine (Dopa)